Sign In
Buy ATXI
$0.300
+0.0300 (+11.11%)
At Close: Jun 22, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
10:34pm, Wednesday, 21'st Apr 2021
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such invest
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
10:09pm, Monday, 19'th Apr 2021
NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors ar
Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?
07:06am, Monday, 19'th Apr 2021
Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
11:30pm, Tuesday, 13'th Apr 2021
NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors ar
ATXI Stock: Over 15% Decrease Pre-Market Explanation
08:18am, Tuesday, 13'th Apr 2021
The stock price of Avenue Therapeutics, Inc. (Nasdaq: ATXI) fell by over 15% pre-market. This is why it happened.
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
06:30am, Tuesday, 13'th Apr 2021
The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA
ATXI Stock: Over 15% Increase Pre-Market Explanation
05:45am, Monday, 12'th Apr 2021
The stock price of Avenue Therapeutics Inc (NASDAQ: ATXI) increased by over 15% pre-market. This is why it happened.
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
08:00am, Friday, 18'th Dec 2020
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced th
Why Fortress Biotech Stock Jumped Today
04:27pm, Thursday, 17'th Dec 2020
One of the company's subsidiaries announced some good news today.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2
02:33pm, Monday, 17'th Aug 2020
Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
11:30am, Friday, 14'th Aug 2020
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
04:53pm, Tuesday, 04'th Aug 2020
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know
09:50pm, Tuesday, 28'th Jul 2020
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.
